glp-1 agonist drugs oral new glp 1 In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron Danuglipron: An Oral GLP-1R Agonist
Description
However, heterogeneity in weight loss response, cost, side effects, and need for injections may limit their use in many pediatric patients
Rybelsus was the first oral GLP-1 approved for diabetes, available in 3mg, 7mg, and 14mg daily tablets
That does not mean every result is proven for every patient
It may be prudent to re-evaluate traditional fasting guidelines in these patients
